AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01764854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1722 (in-patient)
Description: doses between 5 and 60 mg BID may be administered based on tolerability in a CPU setting
Study NCT01764854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (in-patient)
Description: Placebo, size and color matched to experimental drug administered in a CPU
Study NCT01764854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1722 (out-patient)
Description: doses between 5 and 45 mg BID
Study NCT01764854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, size and color matched to experimental drug
Study NCT05299229 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogrpahy and non-invasive monitoring
Description: Study participants will have echocardiography and non-invasive monitoring by chest/back sensors and a finger cuff.
Study NCT03866681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: The dose of sirolimus is adjusted according to monitored serum concentration, maintain Rapamycin concentration ranging from 4 to 10ng/ml.Warfarin was administered orally at a dose of 1mg per day for a year,then gradually reduced to stop.
Study NCT04698044 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hospital Anxiety Depression Scale
Description: HADS is a self-report questionnaire designed to screen the symptoms of anxiety and depression in individuals with medical diseases other than psychiatric illnessesHADS is a self-report questionnaire designed to screen the symptoms of anxiety and depression in individuals with medical diseases other than psychiatric illnesses The 4-point Likert type scale, which consists of 14 items, has 2 subscales. Each of the HADS-Anxiety (HADS-A) and HADS-Depression (HADS-D) subscales has 7 items. The score given for each question varies between 0 and 3. A high score indicates a high level of anxiety and depression. The responses given to the questions are given certain scores, and as a result, a score of 0-7 refers to a normal level, 8-10 to a level at the limit and 11 and above to a high level (abnormal level).
Study NCT00117273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)]
Description: 1 tablet daily
Study NCT00117273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seasonique (LNG/EE and EE)
Description: 1 tablet daily
Study NCT00117273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Portia (LNG/EE)
Description: 1 tablet daily x 28 days
Study NCT02806908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JZP-110
Study NCT02806908 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01443546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dual Trigger
Description: a combination of the two drugs in low dosage (leuprolide acetate 2 mg and hCG 1500 IU).
Study NCT00946088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Progesterone 400 mg per vagina qhs.
Study NCT00403481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil
Description: Olmesartan medoxomil tablets, once daily
Study NCT00403481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil plus Hydrochlorothiazide
Description: Olmesartan medoxomil and hydrochlorothiazide combination tablets, once daily, if necessary
Study NCT00127231 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief alcohol intervention based on Project Treat
Description: The brief intervention will include two sessions that review drinking patterns and behavior change strategies as well as two telephone calls to reinforce session content.
Study NCT00127231 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Hazardous/binge female drinkers will be identified in the Johns Hopkins Hospital HIV clinic and will be randomized to brief intervention or standard care. Outcome measures will include: alcohol/drug use, engagement in an on-site alcohol support group and other substance abuse treatment services, HIV-risk behaviors, HIV disease markers and treatment compliance, and psychiatric symptoms.
Study NCT02962492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide/Exenatide extended release
Description: Eighty (80) patients with T1D will be enrolled and randomized into 4 groups(20 each) to receive placebo, or dapagliflozin, or exenatide (5µg acutely)/Exenatide extended release (long term), or exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin treatments acutely and for 12 weeks
Study NCT02962492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Eighty (80) patients with T1D will be enrolled and randomized into 4 groups(20 each) to receive placebo, or dapagliflozin, or exenatide (5µg acutely)/Exenatide extended release (long term), or exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin treatments acutely and for 12 weeks
Study NCT02962492 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eighty (80) patients with T1D will be enrolled and randomized into 4 groups(20 each) to receive placebo, or dapagliflozin, or exenatide (5µg acutely)/Exenatide extended release (long term), or exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin treatments acutely and for 12 weeks
Study NCT04087993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyglucoferron
Description: intravenous administration
Study NCT04087993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric carboxymaltose
Description: intravenous administration
Study NCT04087993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate
Description: oral administration
Study NCT05576142 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oral examination
Description: Patients underwent oral examination with the recording of DMFT, PSR, PI and presence/absence of mouth breathing.
Study NCT02929589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days
Study NCT02929589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid Medication
Description: 1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days
Study NCT02929589 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 800 milligrams of a placebo pill (containing corn starch) to be taken by mouth every 8 hours as needed for pain
Study NCT02929589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen + Opioid medication
Description: ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days. 1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days
Study NCT03190993 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sugar Sweetened Solid Treatment
Description: Consume Sugar Sweetened Solid Treatment (product) daily.
Study NCT00946088 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Polyethylene glycol&hydrogenated vegetable oil.
Description: Placebo Comparator: Polyethylene glycol 400 distearate \& hydrogenated vegetable oil per vagina qhs.
Study NCT01882088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mucofalk
Description: Mucofalk 15 g/day i.e. 5 g TID per os, 15-20 min before meal
Study NCT00999271 — intervention group
Intervention type: OTHER
Intervention: Incretin hormone - Glucose-dependent insulinotropic polypeptide (GIP)
Description: two different dosages:~* 0.8 pmol/kg/min~* 1.5 pmol/kg/min for 300 minutes
Study NCT00977340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery Rehearsal Treatment
Description: Imagery Rehearsal Therapy
Study NCT00977340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: confrontation
Description: Confrontation
Study NCT00977340 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: imagination
Description: Imagination
Study NCT03490942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: CSI-Glucagon is a room temperature stable, non-aqueous, liquid formulation of glucagon.
Study NCT03490942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo solution is a non-active formulation containing excipients only.
Study NCT03190993 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sugar Sweetened Beverage Treatment
Description: Consume Sugar Sweetened Beverage Treatment (product) daily.
Study NCT01790984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High sugar low starch diet
Study NCT01790984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low sugar high starch diet
Study NCT04502654 — intervention group
Intervention type: DEVICE
Intervention: Actiwatch 2 (Philips Respironics, Murrysville, USA)
Description: Actiwatch 2 is an unobtrusive, waterproof, light sensor and wrist-worn device (weight 16.0g, size 4.3 cm\* 2.3 cm\* 1.0 cm), containing a tri-axial accelerometer able to records a digitally integrated measure of gross motor activity (a piezoelectric sensor to detect vertical accelerations at the wrist between 0.5 and 2.0 g with a frequency response range between 0.35-7.5 Hz). Activity counts from the device reflect the peak acceleration detected over each epoch and are used in determining sleep and wake intervals, which can be used to rest-activity patterns, quality of physical activity and sleep for 15-60 seconds/ epoch, 24 hours/ day, 2 weeks.
Study NCT04083885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Participants will be provided with a virtual reality training program, personalized with respect to their abilities, endurance, needs and treatment goals. They will be trained to use the program and it will be installed in their home or provided at their long-term care facility. Participants will be suggested to perform VR 3-5 times a week for 8 weeks. Sessions will be 20-30 minutes long, depending on tolerance.
Study NCT00213954 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: ultrasound-guidance with echography
Description: Locoregional anesthesia with or without ultrasound guidance practice
Study NCT00585091 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: phenylephrine
Description: All patients undergo repeated phenylephrine infusions during standard up-titration and maintenance of carvedilol treatment.
Study NCT04264299 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T tube drainage
Description: closure of common bile duct over T tube
Study NCT04264299 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary closure
Description: Primary closure of common bile duct
Study NCT04264299 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary closure
Description: Primary closure of common bile duct
Study NCT04264299 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Antegrade stenting
Description: Closure of common bile duct over antegrade plastic biliary stent
Study NCT04264299 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Antegrade stenting
Description: Closure of common bile duct over antegrade plastic biliary stent
Study NCT02304575 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires:~For examinee: European Organization for Research and Treatment of Cancer quality of life questionnaire of 30 items and testicular cancer module of 26 items (EORTC QLQ-30 + QLQ-TC-26), Multidimensional Coping Inventory, The Meaning Test for cognitive function, cognitive orientation questionnaires.~For partner: Multidimensional Inventory of quality of life (QoL) for Adults, Multidimensional Coping Inventory.
Study NCT02304575 — intervention group
Intervention type: OTHER
Intervention: Hormonal Function measurement
Description: Plasma levels of: follicular stimulating hormone (FSH), luteinizing hormone (LH), thyroid-stimulating hormone (TSH), prolactin, free androgen index.
Study NCT01472588 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DPP lifestyle intervention-Community Health Coach (CHWs)
Description: Lifestyle counseling. During a 16 month period, the behavioral weight loss program (n=24 sessions of the DPP lifestyle intervention) is delivered by CHWs in group format in community settings.
Study NCT01472588 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DPP Lifestyle intervention--health professionals/(PHCs)
Description: Lifestyle counseling. During a 16 month period, the behavioral weight loss program (n=24 sessions of the DPP lifestyle intervention) is delivered by PHCs in group format in community settings.
Study NCT01472588 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Self Help
Description: Public education/information booklet on weight management.
Study NCT01421979 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Drink, Taurine, Caffeine
Study NCT02862665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iron isomaltoside 1000 (Monofer®)
Description: The patients will receive iron isomaltoside 1000 (Monofer®) as an i.v. infusion of 1000 mg (diluted with normal saline, 10 mg/ml) twice; 3 days before surgery and 3 days after surgery. They will receive iron isomaltoside 1000 (Monofer®) 1000 mg over 15 min.
Study NCT02862665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline 100 ml
Description: The patients will receive normal saline 100 ml as an i.v. infusion twice; 3 days before surgery and 3 days after surgery. They will receive normal saline 100 ml over 15 min.
Study NCT03839004 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated approach to pregnancy
Description: Yoga classes, mindfulness classes, coaching, nutrition counselling and osteopathy
Study NCT02549326 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D
Study NCT00711776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: New formulation
Description: New formulation of Aciclovir Cream 5% scheduled to be substituted to Current formulation in Japan
Study NCT00711776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Current formulation
Description: Current formulation of Aciclovir Cream 5% in Japan
Study NCT02549326 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01729078 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: three different diets ( high fat-low carb-low fiber/high carb-low fat - high fiber/high carb-low fat-low fiber)
Study NCT00390871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl/Dexmedetomidine
Study NCT00390871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl/Propofol
Study NCT00390871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Study NCT04287660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells
Description: * clarithromycin: 500mg, PO, twice daily, on days 1\~21 for a 28-day cycle.~* lenalidomide: 25mg, PO, on days 1\~21 for a 28-day cycle. dexamethasone: 40mg, PO on days 1,8,15 and 22 for a 28-day cycle. BCMA CAR T cell: (2-3)×10E7/kg, intravenously infusion.~* Doses should be adjusted according to renal function.
Study NCT01966120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BF-200 ALA gel
Description: BF-200 ALA was applied over 1-2 fields of approximately 20 cm² in total, allowed to dry for approximately 10 minutes, and covered with occlusive tape material for 3 h.
Study NCT01966120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BF-200 ALA gel
Description: The reference product was a placebo (a nanoemulsion gel formulation similar to the Investigational Medicinal Product (IMP), but without the active ingredient). The placebo was packaged, assigned to each patient, and administered in the same way as the IMP.
Study NCT01966120 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic therapy with BF-RhodoLED
Description: After cleaning the lesions, the entire treatment field(s) were illuminated using the novel narrow spectrum BF-RhodoLED lamp, a red light illumination source (approximately 635 nm) developed by Biofrontera, until a total light dose of 37 J/cm² (per treated field) was achieved.
Study NCT04548895 — intervention group
Intervention type: DEVICE
Intervention: Observational measurement of biometric data. No change to health care provided.
Description: Emfit devices will be installed once after enrollment under each participant's mattress and left to record automatically without further intervention. The participants will wear their Biostrap wristbands consistently, ideally 24 hours a day, 7 days a week, for 2 months.~A virus panel will be upon enrollment (baseline) and then every two weeks (± 3 days, or on the closest convenient sampling day if the LTCF is testing all residents on the same day) for a maximum of 5 times during the two-month period. Using polymerase chain reaction or next generation sequencing, the virus panel will detect COVID-19 and 12 other common respiratory viruses that may cause similar symptoms and similar biometric signatures. These include influenza A and B, parainfluenza types 1 through 4, respiratory syncytial virus, non-COVID coronavirus, rhinovirus, adenovirus, bocavirus and metapneumovirus.
Study NCT01966120 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Photodynamic therapy with BF-RhodoLED
Description: After cleaning the lesions, the entire treatment field(s) were illuminated using the novel narrow spectrum BF-RhodoLED lamp, a red light illumination source (approximately 635 nm) developed by Biofrontera, until a total light dose of 37 J/cm² (per treated field) was achieved.
Study NCT02482688 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A New Rehabilitation Treatment following Stroke
Description: A randomised control design, comparing individuals who will receive visual unisensory stimulation alone (i.e., the control rehabilitation) and those who receive multisensory stimulation (i.e., the experimental rehabilitation), will be used to assess the effects of multisensory rehabilitation on learning, performance accuracy and speed in participants with neglect/extinction.
Study NCT02807766 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavior modification
Description: Each group has 30 subjects and experiences six months' training.
Study NCT02807766 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior modification and sensory integration training
Description: Each group has 30 subjects and experiences six months' training.
Study NCT02807766 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior modification and applied behavioral analysis
Description: Each group has 30 subjects and experiences six months' training.
Study NCT02807766 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior modification and TEACCH
Description: Each group has 30 subjects and experiences six months' training.
Study NCT02482688 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A New Rehabilitation Treatment following Stroke
Description: A randomised control design, comparing individuals who will receive visual unisensory stimulation alone (i.e., the control rehabilitation) and those who receive multisensory stimulation (i.e., the experimental rehabilitation), will be used to assess the effects of multisensory rehabilitation on learning, performance accuracy and speed in participants with neglect/extinction.
Study NCT01775111 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive Training
Study NCT01775111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength Training
Study NCT01775111 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FortiFit
Study NCT01225198 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-Vitamin/Mineral Supplement
Description: A broad-spectrum vitamin/mineral supplement designed for children and adults with autism
Study NCT01225198 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Liquid Placebo
Description: The placebo was formulated to look and taste like the intervention supplement. A small amount of beta-carotene was used for coloring. Natural cherry, citric acid, and a proprietary blend of natural flavors were used for flavoring to create a vitamin-like after-taste. Sucralose was used as a sweetener and the same preservatives were included (potassium sorbate, sodium benzoate).
Study NCT04674215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Turning in Bed
Description: Preoperative Turning in Bed Training
Study NCT04674215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobilization
Description: Preoperative Mobilization Training
Study NCT04674215 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: information
Description: Routine Clinical Care
Study NCT04674215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: information
Description: Routine Clinical Care
Study NCT03451890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2730
Description: oral capsule
Study NCT03451890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsule